Tag
Statins
17 genetic variants with this tag.
| RSID | Gene | Description | Category | ||
|---|---|---|---|---|---|
| rs11591147 | PCSK9 R46L | Loss-of-function variant that naturally lowers LDL cholesterol by 15-28% and ... | Atherogenic Lipoproteins | Established | |
| rs12487736 | SCAP SCAP Val798Ile | Missense variant in the SCAP cholesterol-sensor gene (Val798Ile) | Atherogenic Lipoproteins | Moderate | |
| rs12713559 | APOB APOB R3558C | Rare APOB missense variant reducing LDL-receptor binding affinity by ~40-50%,... | Cholesterol & Lipoproteins | Moderate | |
| rs185392267 | PCSK9 Arg96Cys | Gain-of-function missense variant in PCSK9 that increases intracellular LDL r... | Cholesterol & Lipoproteins | Strong | |
| rs505151 | PCSK9 E670G | Common missense variant in PCSK9 exon 12 where the rare G allele raises LDL c... | Atherogenic Lipoproteins | Moderate | |
| rs28942083 | LDLR Cys667Tyr | Pathogenic LDLR missense variant abolishing LDL receptor surface expression, ... | Cholesterol & Lipoproteins | Established | |
| rs5925 | LDLR LDLR Expression Co-variant | Synonymous variant in LDLR exon 13 that modulates mRNA splicing efficiency in... | Atherogenic Lipoproteins | Moderate | |
| rs20455 | KIF6 Trp719Arg | Missense variant in kinesin family member 6; the Arg allele was associated wi... | Coronary Artery Disease & Atherosclerosis | Moderate | |
| rs6008845 | PPARA PPARA intronic C/T | Regulatory PPARA variant where TT homozygotes with type 2 diabetes experience... | Atherogenic Lipoproteins | Strong | |
| rs6511720 | LDLR Intron 1 | Common regulatory variant in the LDL receptor gene affecting LDLR expression,... | Atherogenic Lipoproteins | Strong | |
| rs688 | LDLR Asn591Asn (c.1773C>T) | Synonymous LDLR variant that disrupts exon 12 splicing, reduces LDL receptor ... | Atherogenic Lipoproteins | Strong | |
| rs2231142 | ABCG2 Q141K | Reduces ABCG2 transporter function affecting rosuvastatin levels and uric aci... | Pharmacogenomics | Established | |
| rs9818870 | MRAS | 3' UTR variant near miRNA binding sites in MRAS, associated with ~15% increas... | Coronary Artery Disease & Atherosclerosis | Strong | |
| rs35599367 | CYP3A4 *22 | Intronic splice variant causing ~50% reduced CYP3A4 mRNA expression, affectin... | Pharmacogenomics | Established | |
| rs4148323 | UGT1A1 *6 Gly71Arg | Phase II glucuronidation enzyme that metabolizes bilirubin and many drugs inc... | Pharmacogenomics | Established | |
| rs4149056 | SLCO1B1 *5 | Statin transport - affects muscle side effect risk with statins | Pharmacogenomics | Established | |
| rs55785340 | CYP3A4 *2 | Missense variant reducing CYP3A4-mediated nifedipine clearance, causing eleva... | Pharmacogenomics | Moderate |